Registry for patients with lung cancer
Lung Cancer Registry
This study is collecting health information from lung cancer patients to see how their condition changes over time without affecting their regular treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Salzburg, State of Salzburg and 2 other locations) |
| Trial ID | NCT04654364 on ClinicalTrials.gov |
What this trial studies
This registry collects and analyzes medical data from patients diagnosed with various stages of lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It aims to gather longitudinal follow-up data on patient survival and tumor progression by extracting information from existing medical charts. The registry does not require any additional diagnostic or therapeutic measures beyond standard care, ensuring that participation does not interfere with routine treatment. Patient confidentiality is maintained through unique identifiers assigned upon enrollment.
Who should consider this trial
Good fit: Ideal candidates for this registry are adults aged 18 and older with stage III or IV NSCLC or limited/extensive stage SCLC.
Not a fit: Patients with lung cancer who are not diagnosed with stage III or IV NSCLC or SCLC may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of lung cancer progression and treatment outcomes, potentially leading to improved patient care.
How similar studies have performed: Other observational registries have successfully contributed to the understanding of cancer treatment outcomes, indicating that this approach is both valid and beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * stage III A-C and IV A-B NSCLC * limited disease (LD) and extensive disease (ED) SCLC) * patients ≥ 18 years Exclusion Criteria: \- Due to the non-interventional design of the registry there are no specific exclusion criteria.
Where this trial is running
Salzburg, State of Salzburg and 2 other locations
- Universitätsklinik für Innere Medizin III, PMU Salzburg — Salzburg, State of Salzburg, Austria (Recruiting)
- Univ.-Klinik für Innere Medizin V, Hämatologie/Onkologie LKH-Innsbruck / Universitätskliniken — Innsbruck, Tyrol, Austria (Recruiting)
- Kepler Universitätsklinikum GmbH, Med. Campus III, Klinik für Lungenheilkunde / Pneumologie — Linz, Upper Austria, Austria (Recruiting)
Study contacts
- Study coordinator: Daniela Wolkersdorfer
- Email: office@agmt.at
- Phone: +436626404412
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.